Epigral is an integrated specialty-chemicals compounder temporarily trapped in a brutal downcycle—its moat is built, but margins must survive Chinese dumping and weak realizations.
Overview
Epigral Limited (EPIGRAL.NS) is a transformed Indian chemicals company that has evolved (rebranded from Meghmani Finechem in FY23–24) from a local chlor-alkali producer into a globally competitive, multi-product platform anchored by a **165-acre, highly automated, deeply integrated Dahej complex**. Its legacy Chlor-Alkali business produces caustic soda/potash at **~400k–421k TPA** caustic soda capacity (plus 21k TPA caustic potash) serving diversified industrial users, but the core value creation now comes from Derivatives & Specialty Chemicals. This segment focuses on **import substitution** and chlorine valorization into CPVC resin/compound, ECH (via a sustainable glycerol route), chloromethanes, hydrogen peroxide, and the newly launched chlorotoluenes chain aimed at pharma/agro intermediates. The pivot is visible in mix: Derivatives & Specialty grew from **~25% of revenue (FY22)** to **~56% by H1 FY25**, positioning the company to reduce commodity cyclicality and expand margins over time—though the current cycle is pressuring realizations and near-term profitability.